Clinical Trials Logo

Prostatic Diseases clinical trials

View clinical trials related to Prostatic Diseases.

Filter by:

NCT ID: NCT06190899 Recruiting - Prostate Cancer Clinical Trials

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Start date: January 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.

NCT ID: NCT05941260 Completed - Clinical trials for Prostate Hyperplasia

Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics

Start date: July 15, 2023
Phase:
Study type: Observational

The enlargement of the prostate is responsible for voiding dysfunction in men, and especially elderly men. The primary surgical treatment for symptomatic benign prostatic hypertrophy (BPH) was transurethral resection of the prostate (TURP). However, current resection techniques are predominantly experience-based and judgment-based, with little evidence to support the most effective portion of the prostate to be respected. So, the investigators plan through the study to construct a flow diagram to evaluate the amount of tissue needed to be resected to improve voiding flow dynamics.

NCT ID: NCT05902637 Recruiting - Prostate Cancer Clinical Trials

The Efficacy Of Mapping For Cognitive Prostate Biopsy

MAPROSTATE
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Today, many centers still perform Magnetic Resonance Imaging (MRI) cognitive prostate biopsy. The efficacy of detecting clinically significant prostate cancer, which is thought to be due to the experience of the urologist who performed the sampling and the difference in experience of the radiologists who performed the Multiparametric Prostate Magnetic Resonance (MPMR) evaluation, has been reported between 25% and 34% in the literature. In order to eliminate this reporting and sampling difference, The goal of this interventional study is to compare the effectiveness of Multiparametric Prostate Magnetic Resonance (MPMR) Imaging routinely taken before biopsy with a single-center randomized and prospective study and prostate biopsies to be performed by the same urologist with the mapping technique created by a single genitourinary radiologist working in our center with standard cognitive prostate biopsy and to contribute to the literature Type of study: Clinical trial participant population: Male patients with elevated serum Prostate Specific Antigen (PSA) or indicated prostate biopsy by Magnetic Resonance Imaging (MRI) imaging and underwent Multiparametric Prostate Magnetic Resonance (MPMR) before the procedure Participants will undergo transrectal prostate biopsy with or without mapping, Researches will compare to see if the cancer detection rates differ

NCT ID: NCT05834270 Completed - Prostatic Neoplasms Clinical Trials

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

NCT ID: NCT05803096 Completed - Prostate Cancer Clinical Trials

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Start date: December 12, 2021
Phase: Phase 4
Study type: Interventional

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.

NCT ID: NCT05682742 Active, not recruiting - Prostate Cancer Clinical Trials

Clinical Investigation of the da Vinci Surgical System

Start date: December 12, 2022
Phase: N/A
Study type: Interventional

This prospective, multicenter, single-arm study is being conducted to confirm safety, effectiveness, and usability of da Vinci Surgical System in performing robotic-assisted surgical procedures.

NCT ID: NCT05574647 Not yet recruiting - Prostate Cancer Clinical Trials

Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer

IP7-PACIFIC
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the role of biparametric MRI and image-fusion targeted biopsies for the detection of prostate cancer. To determine whether biparametric MRI (bpMRI) could be recommended as an alternative to multiparametric MRI (mpMRI) for the detection of clinically significant prostate cancers in patients at risk. To determine whether image-fusion targeted biopsy is better than visual-registration (cognitive) targeted biopsy at detecting clinically significant prostate cancers in patients requiring prostate biopsy due to a suspicious MRI.

NCT ID: NCT05470127 Not yet recruiting - Prostate Disease Clinical Trials

Evaluation of a Soft Tissue Biopsy System for Trans-rectal and Trans-perineal Biopsy of the Prostate

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Currently used biopsy devices do not predictably obtain full cores of tissue and the tissue obtained is often fragmented and disrupted making it difficult for pathological review. This post-market study will assess the utility of the SUREcore biopsy needle and the coreCARE specimen retrieval device versus a standard of care biopsy needle and the typical tissue container used in urology offices and clinics today.

NCT ID: NCT05413850 Recruiting - Prostate Cancer Clinical Trials

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Start date: July 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

NCT ID: NCT05399940 Completed - Prostate Cancer Clinical Trials

The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

Purpose: To find the correlation between hemogram parameters and Delta Neutrophil Index(DNI) and Serum PSA in patients presenting with the diagnosis of acute prostatitis. Material-Metod: Serum PSA levels and hemogram parameters of patients who came to the urology outpatient clinic in January 2018 and May 2022 and were diagnosed with prostatitis were collected retrospectively.